Metraipolis › archive › dc_360e59c68cb3
Interlaboratory comparison for the Filovirus Animal Nonclinical Group (FANG) anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay — Europe PMC PMID:32841291
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/32841291
- DOI
- 10.1371/journal.pone.0238196
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-07T16:16:52.408Z
- SHA-256 of the archived text
440f6a83f0306d438b69716f981ebee318582c05bfe9a78c017bb7736f6038ac- Stable URL of this page
https://metraipolis.com/documento/dc_360e59c68cb3
How to cite
Interlaboratory comparison for the Filovirus Animal Nonclinical Group (FANG) anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay — Europe PMC PMID:32841291 — Europe PMC (en), https://europepmc.org/article/MED/32841291 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_360e59c68cb3 (Metraipolis archive dc_360e59c68cb3, sha256 440f6a83f0306d438b69716f981ebee318582c05bfe9a78c017bb7736f6038ac)
BibTeX
@misc{dc360e59c68cb3,
title = {Interlaboratory comparison for the Filovirus Animal Nonclinical Group (FANG) anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay — Europe PMC PMID:32841291},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/32841291},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_360e59c68cb3; sha256 440f6a83f0306d438b69716f981ebee318582c05bfe9a78c017bb7736f6038ac},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32841291. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
The need for an efficacious vaccine against highly pathogenic filoviruses was reinforced by the devastating 2014-2016 outbreak of Ebola virus (EBOV) disease (EVD) in Guinea, Sierra Leone, and Liberia that resulted in over 28,000 cases and over 11,300 deaths. In addition, the 2018-2020 outbreak in the Democratic Republic of the Congo currently has over 3,400 cases and over 2,200 deaths. A fully licensed vaccine and at least one other investigational vaccine are being deployed to combat this EVD outbreak. To support vaccine development and pre-clinical/clinical testing a Filovirus Animal Nonclinical Group (FANG) human anti-EBOV GP IgG ELISA was developed to measure anti-EBOV GP IgG antibodies. This ELISA is currently being used in multiple laboratories. Reported here is a characterization of an interlaboratory statistical analysis of the human anti-EBOV GP IgG ELISA as part of a collaborative study between five participating laboratories. Each laboratory used similar method protocols and reagents to measure anti-EBOV GP IgG levels in human serum samples from a proficiency panel consisting of ten serum samples created by the differential dilution of a serum sample positive for anti-GP IgG antibodies (BMIZAIRE105) with negative serum (BMI529). The total assay variability (inter- and intra-assay variability) %CVs observed at each laboratory ranged from 12.2 to 30.6. Intermediate precision (inter-assay variability) for the laboratory runs ranged from 8.9 to 21.7%CV and repeatability (intra-assay variability) %CVs ranged from 7.2 to 23.7. The estimated slope for the relationship between log10(Target Concentration) and the log10(Observed Concentration) across all five laboratories was 0.95 with a 90% confidence interval of (0.93, 0.97). Equivalence test results showed that the 90% confidence interval for the ratios for the sample-specific mean concentrations at the five individual labs to the overall laboratory consensus value were within the equivalence bounds of 0.80 to 1.25 for each laboratory and test sample, except for six test samples from Lab D, two samples from Lab B1, and one sample from Lab B2. The mean laboratory concentrations for Lab D were less than those from the other laboratories by 20% on average across the serum samples. The evaluation of the proficiency panel at these laboratories provides a limited assessment of assay precision (intermediate precision, repeatability, and total assay variability), dilutional linearity, and accuracy. This evaluation suggests that the within-laboratory performance of the anti-EBOV GP IgG ELISA as implemented at the five laboratories is consistent with the intended use of the assay based on the acceptance criteria used by laboratories that have validated the assay. However, the assessment of between-laboratory performance revealed lower observed concentrations at Lab D and greater variability in assay results at Lab B1 relative to other laboratories. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2020 (prima pubblicazione 2020-08-25). Identificativi: PMID 32841291 · PMCID PMC7447032 · DOI 10.1371/journal.pone.0238196. Pagina: https://europepmc.org/article/MED/32841291 — https://doi.org/10.1371/journal.pone.0238196. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-07T16:12:28.090Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.